Vertex Pharmaceuticals Missed Expectations

Vertex Pharmaceuticals (VRTX) reported earnings of $4.11 per share on revenue of $2.77 billion for the first quarter ended March 2025. The consensus earnings estimate was $4.25 per share on revenue of $2.82 billion. The Earnings Whisper number was $4.38 per share. The company missed expectations by 6.16% while revenue grew 2.96% on a year-over-year basis.

The company said it expects 2025 revenue of $11.85 billion to $12.00 billion. The company's previous guidance was revenue of $11.75 billion to $12.00 billion and the current consensus revenue estimate is $11.86 billion for the year ending December 31, 2025.

Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets.